Scarica l'app Stockscreener
10.29
4.98%
0.445
Precedente Chiudi:
$9.84
Aprire:
$9.97
Volume 24 ore:
320.41K
Relative Volume:
0.65
Capitalizzazione di mercato:
$199.60M
Reddito:
$1.54M
Utile/perdita netta:
$-84.53M
Rapporto P/E:
-1.7689
EPS:
-5.8145
Flusso di cassa netto:
$-73.65M
1 W Prestazione:
+2.38%
1M Prestazione:
+15.03%
6M Prestazione:
+39.22%
1 anno Prestazione:
+6.49%
Intervallo 1D:
$9.895
$10.38
Intervallo di 1 settimana:
$9.7301
$10.75
Portata 52W:
$7.12
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Nome
Corbus Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
617-963-0103
Indirizzo
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.32 | 193.22M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
550.01 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
841.32 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,051.00 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
149.05 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.01 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Iniziato | Wedbush | Outperform |
| 2024-07-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-06-26 | Iniziato | B. Riley Securities | Buy |
| 2024-06-03 | Reiterato | Oppenheimer | Outperform |
| 2024-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-08 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2020-09-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-03-26 | Iniziato | Nomura | Buy |
| 2019-04-05 | Iniziato | Jefferies | Buy |
| 2019-03-20 | Iniziato | Oppenheimer | Outperform |
| 2019-01-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-10-24 | Iniziato | B. Riley FBR | Buy |
| 2018-01-19 | Iniziato | Raymond James | Outperform |
| 2017-12-14 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Reiterato | Noble Financial | Buy |
| 2017-09-29 | Ripresa | Noble Financial | Buy |
| 2017-03-30 | Reiterato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-11 | Reiterato | Noble Financial | Buy |
Mostra tutto
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
CRBP Q2 2026 Earnings: Wider-Than-Expected Loss of $1.81 Per Share, Yet Shares Advance 3.96%Earnings Yield Spread - Vinanet
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Corbus Pharmaceuticals (CRBP) Holds Near $10.09 as Traders Eye $10.59 ResistanceOption Breadth - Vinanet
Corbus Pharmaceuticals (CRBP) Holds Near $10 as Buyers Defend Key SupportCovered Call ETF - Vinanet
Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake - Stock Titan
Price-Driven Insight from (CRBP) for Rule-Based Strategy - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates - Investing.com
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Canada
CRBP Insider Buying: Chief Business Officer Nishant Saxena Purch - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Chief Business Officer Nishant Saxena acquires 2,600 shares worth $25,037.44 - Bitget
Research Analysts Set Expectations for CRBP Q3 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock - MarketBeat
Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP) - TradingView
Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock News Today - TradingKey
CRBP (NASDAQ: CRBP) insider plans 12,000-share sale via Stifel - Stock Titan
CRBP (CRBP) holder files to sell 17,000 Nasdaq-traded shares - Stock Titan
CRBP Maintained by Oppenheimer -- Price Target Lowered to $48.00 - GuruFocus
Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
CRBP Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $35 - Moomoo
HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating - Moomoo
Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ: CRBP) ramps R&D to $51M as cash backs key trials - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan
Corbus Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals (CRBP) Holds Gains as Biotech Momentum BuildsLow Vol ETF - Vinanet
Corbus Pharmaceuticals Announces Last Patient Last Visit In Canyon-1 Study Of CRB-913 For The Treatment Of Obesity - marketscreener.com
Corbus Pharmaceuticals (CRBP) Completes Final Patient Visit in C - GuruFocus
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statement - Bitget
Obesity Treatment Study Reaches Final Visit; Corbus Data Expected in September - Stock Titan
CRBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? - StockInvest.us
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
0.76%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):